AU2017394679A1 - Natural combination hormone replacement formulations and therapies - Google Patents

Natural combination hormone replacement formulations and therapies Download PDF

Info

Publication number
AU2017394679A1
AU2017394679A1 AU2017394679A AU2017394679A AU2017394679A1 AU 2017394679 A1 AU2017394679 A1 AU 2017394679A1 AU 2017394679 A AU2017394679 A AU 2017394679A AU 2017394679 A AU2017394679 A AU 2017394679A AU 2017394679 A1 AU2017394679 A1 AU 2017394679A1
Authority
AU
Australia
Prior art keywords
estradiol
progesterone
subject
auc
estrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2017394679A
Other languages
English (en)
Inventor
Julia M. Amadio
Brian A. Bernick
Sebastian MIRKIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TherapeuticsMD Inc
Original Assignee
TherapeuticsMD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TherapeuticsMD Inc filed Critical TherapeuticsMD Inc
Publication of AU2017394679A1 publication Critical patent/AU2017394679A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017394679A 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies Pending AU2017394679A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (1)

Publication Number Publication Date
AU2017394679A1 true AU2017394679A1 (en) 2019-06-13

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017394679A Pending AU2017394679A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Country Status (11)

Country Link
EP (1) EP3548036A4 (ja)
JP (1) JP2020504093A (ja)
KR (1) KR20200018383A (ja)
CN (1) CN110290793A (ja)
AU (1) AU2017394679A1 (ja)
BR (1) BR112019011655A2 (ja)
CA (1) CA3045024A1 (ja)
IL (1) IL267023A (ja)
MX (1) MX2019006513A (ja)
RU (1) RU2019115913A (ja)
WO (1) WO2018136161A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP2017516768A (ja) * 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法

Also Published As

Publication number Publication date
RU2019115913A (ru) 2021-01-15
CA3045024A1 (en) 2018-07-26
RU2019115913A3 (ja) 2021-03-19
EP3548036A4 (en) 2020-06-17
MX2019006513A (es) 2019-08-14
BR112019011655A2 (pt) 2019-10-22
JP2020504093A (ja) 2020-02-06
WO2018136161A9 (en) 2019-08-22
WO2018136161A1 (en) 2018-07-26
IL267023A (en) 2019-07-31
EP3548036A1 (en) 2019-10-09
KR20200018383A (ko) 2020-02-19
CN110290793A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
US20180221389A1 (en) Natural combination hormone replacement formulations and therapies
US10806740B2 (en) Natural combination hormone replacement formulations and therapies
US20190247401A1 (en) Natural combination hormone replacement formulations and therapies
US11103513B2 (en) Natural combination hormone replacement formulations and therapies
US10668082B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
Anawalt et al. Combined nestorone–testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men
Vogler et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188
US11266661B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
US20200155465A9 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
AU2017394679A1 (en) Natural combination hormone replacement formulations and therapies
US20230302015A1 (en) Natural combination hormone replacement formulations and therapies
CA3007636A1 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
Label Label Information Yaz
Bayer WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
Label Label Information Loryna
Start Label Information Drospirenone And Ethinyl Estradiol
Rybacki HOW SUPPLIED
BR112016009008B1 (pt) Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol